Weight-loss medicines: the verification duties the demand data just made urgent

What does the demand data show?

The finding which generated trade coverage in July 2026 provides the starting point. A survey of just over 1,000 British weight-loss medicine users, conducted by the digital healthcare provider Zava, found that 21 per cent, being approximately one in five, held no prescription from a healthcare professional for the medicine they were taking. The same survey recorded around one in six purchasing doses through general e-commerce platforms and just under 12 per cent sourcing them through social media platforms or influencers.

A separate survey of 2,000 UK adults conducted by Atomik Research placed the figures higher among injection users, at 41 per cent having sourced pens online without a prescription and 35 per cent having obtained them through a family member or friend. It is worth noting that sharing a prescription-only medicine between friends constitutes a supply which most participants would not recognise as such, which is a substantial part of why the practice persists.

The academic picture corresponds to the commercial polling. Research led by UCL, published in early 2026 and based on a representative survey of 5,260 adults, estimated that 1.6 million people in Great Britain used weight-loss drugs in the year to early 2025, with a further 3.3 million interested in commencing, and found approximately one in seven users taking products not licensed for weight loss at all, among them the off-label diabetes formulations. The researchers' own framing carries the operational implication, namely that substantial numbers of people are taking these drugs outside medical supervision and that NHS prescribing data captures only a fraction of the picture.

London illustrates the market's shape through a single contrast recorded in a London Assembly Health Committee report in March 2026, comprising approximately half a million potentially eligible Londoners, around 3,000 receiving the medicines on the NHS as of late 2025, and tens of thousands estimated to be purchasing privately, a disparity which the committee characterised as a two-tier system. The same report gathered the behaviours which any online provider must design against, including reports of people misstating their weight to obtain supplies from online pharmacies, and purchases made through social media and beauty salons.

Read collectively, the surveys describe a market in which a substantial minority of those presenting to a service have already obtained, or could readily obtain, the same medicine subject to no checks whatever. That is the context within which a provider's verification either carries meaning or does not. Our market analysis addresses how demand reached this position, whilst the present article concerns the duties which follow from it.

What is the regulatory temperature?

Elevated, and rising over a two-year period. The GPhC strengthened its guidance for online pharmacy services in February 2025, ending questionnaire-only prescribing for high-risk categories with weight-loss medicines named prominently. The full framework is examined in our remote prescribing article, and its central requirement is independent verification in preference to reliance upon self-report.

The MHRA has meanwhile been assembling the clinical risk file, issuing warnings in June 2025 that weight-loss medicines may reduce the effectiveness of oral contraceptives, that effects in pregnancy are not established, and that GLP-1 medicines may be associated with pancreatitis. Clinicians in acute medicine have reported serious complications among people who purchased the drugs online, and NHS England's medical director had already described the medicines as being used inappropriately in 2024. In evidence gathered by the London Assembly, both the MHRA and the GPhC are recorded as concerned that certain providers set internal prescribing targets for weight-loss medicines and fail to identify patients for whom GLP-1 treatment is inappropriate, which represents the closest approximation regulators ordinarily offer to naming a business model.

The enforcement logic follows the pattern tracked across GPhC enforcement generally. Where a category combines high demand, high margin and documented harm, regulatory attention concentrates upon whether providers' checks are genuine. A weight-loss service's verification records accordingly constitute clinical governance rather than administration, and determine which side of the regulators' analysis the provider occupies.

The prescribing-targets concern warrants unpacking, since it identifies a structural failure rather than an individual bad actor. A target need not take the form of a quota on a whiteboard. It may consist of a conversion dashboard visible to the clinical team, a bonus geared to approvals, a funnel review treating refusals as leakage, or simply a rota sized such that declining takes longer than approving. The safeguard is prescriber independence rendered structural, comprising prescribers remunerated without reference to approval rates, refusal rates reviewed as a quality signal rather than a performance concern, and a governance line of the kind mapped in our clinic-plus-pharmacy guide, within which the clinical decision and the commercial interest are visibly separated. Were a regulator to reconstruct an incentive structure from payroll and dashboards, nothing should be found which leans upon the prescriber.

What did the GPhC publish in 2026?

Two documents materially raised the stakes during 2026, and both should be read by anyone operating in this category.

On 24 April 2026 the regulator published a themed review, Weight management medicines and services, a review of GPhC inspections and concerns, drawing on inspection reports and concerns received between January 2024 and December 2025. Its findings describe the failure pattern precisely, comprising weaknesses in risk assessments and clinical governance arrangements, incomplete or insufficient patient consultation records, inconsistent processes for independently verifying weight and BMI, poor communication, and limited arrangements for ongoing clinical follow up and customer support.

The review sets out six recommended actions, which together constitute the most useful specification currently available for anyone building or auditing a service.

Two features of that list deserve emphasis because they extend beyond the verification question. Due diligence upon third party prescribing services places responsibility upon the pharmacy for the prescriber arrangements it relies upon, which bears directly upon the contracted-prescriber model most services adopt. And specific consideration of vulnerable groups including individuals with eating disorders is the clearest statement yet that eligibility screening must actively identify people for whom treatment is inappropriate, rather than confirming that a threshold was met.

The regulator's Chief Pharmacy Officer framed the review as concerning more than compliance, describing strengthened governance, enhanced clinical safeguards and improved transparency as what makes a service safe, reliable and person-centred. A service reading the six actions as an audit checklist has taken the useful part. A service reading them as a design specification has taken the point.

A third development completes the picture. On 18 June 2026 the GPhC joined the MHRA and the Advertising Standards Authority in a statement reminding businesses that prescription-only medicines may not be advertised to the public, extending the warning to pipeline medicines which do not yet hold a licence. The themed review had already identified advertising of weight management services and medicines as a substantial share of the concerns received, including reports of pharmacies paying influencers to promote them. The advertising boundary is accordingly being enforced by three bodies simultaneously within this category, and its interaction with patient testimonials is examined in our reviews article.

What are the six verification gates?

A defensible weight-loss service verifies six matters and can evidence its reasoning for each. The table maps the framework, and the discussion which follows takes the gates in turn.

Gate 2 attracts the greatest market pressure and receives its own treatment below. Gate 3 carries the counselling content which the MHRA's warnings now define, and a service prescribing to a woman of childbearing age without documenting the contraception discussion is disregarding a named regulatory warning. Eating disorder screening is the point at which a weight-loss service's ethics are genuinely tested, since the applicants the screen exists to protect are those most motivated to pass it.

In practice this requires screening constructed around patterns rather than individual answers, including applications at or near the eligibility threshold, weight histories which do not reconcile with the timeline offered, rapid reapplication following refusal, and requests whose urgency is disproportionate to the clinical picture. It further requires a defined escalation path, a named clinician reviewing flags, authority to decline without commercial override, and signposting to appropriate support delivered with care, since the person generating a flag is a patient rather than a fraud case.

Gate 4 addresses the behaviour the surveys identified. In a market where a third of users obtain supply through friends and family, the applicant may already be taking the medicine, and adding a legitimate supply on top of an informal one constitutes a harm which checks can prevent. Gate 5 represents the pharmacy's own contribution to the integrity of the supply chain. Gate 6 distinguishes treatment from retail, since the demand data demonstrates what unsupervised use produces at population scale, and a provider whose involvement concludes at dispatch has constructed supervised access to an unsupervised experience.

What is the self-report problem?

Operationally, that admits several forms. Video consultation with the measurement observed or credibly assessed. Corroboration against GP records or a summary care record where consent and access permit. Photographic evidence, though only within a framework which accounts for manipulation and, more importantly, for the dignity of the person supplying it. And consistency checks over time, since a returning patient whose reported weight and dose response fail to reconcile is conveying information.

None of these is sufficient in isolation. The standard is not perfection, however, but a process which the provider can defend as genuinely independent of the applicant's self-interest, applied consistently, and recorded.

How do the gates map onto the patient journey?

A framework becomes applicable only once sequenced, and the following describes where each gate sits within an operating service.

At application. Identity and age verification run first, before clinical data is collected, since assessing a person who may not exist serves no purpose. Duplication checks run against the provider's own records at the same moment.

At consultation. Independent measurement occurs here, whether video-based or record-corroborated, alongside the structured suitability assessment, the pregnancy and contraception discussion for applicable patients, the supply-history question asked plainly, and eating disorder screening integrated throughout rather than appended. The prescriber's decision is recorded with reasons in either direction.

At first supply. Counselling covering the MHRA-flagged risks in language the patient will retain, the side effects warranting cessation, the titration schedule and the reasons why advancing it is hazardous, and the means of contacting the service between reviews.

At every repeat. A review genuinely capable of stopping treatment, with weight and response reconciled against the record, side effects surveilled, and the interval enforced, since a repeat issued early without explanation represents a dose unaccounted for.

Continuously. The monitoring machinery, recalls which fire when reviews are missed, and aggregate governance permitting the superintendent to observe refusal rates, flag patterns and interval breaches across the service rather than one file at a time.

Sequenced in this manner, the gates cost the honest patient a few minutes and cost the dishonest application everything, which is the correct asymmetry. A service finding its verification burdensome for legitimate patients has generally ordered the gates incorrectly rather than constructed too many of them.

What does the oral era change?

On 6 July 2026 the oral formulation of Wegovy went on sale in UK pharmacies through private weight-management programmes, following MHRA approval in June. The demand effect was anticipated by the sector itself, in that a survey of 310 pharmacy owners published the same week recorded approximately three quarters expecting a surge in demand and 49 per cent having already observed increased patient queries. The finding most relevant here sits alongside those, namely that 97 per cent of surveyed pharmacies were concerned that the tablet would increase fake or unlicensed weight-loss products on the black market.

That concern is well founded on first principles. A tablet is more convincingly counterfeited than an injection pen, more readily split from a pack and sold in small quantities, more easily shared, and more easily passed through the informal networks which the surveys already show supplying a third of users.

For a legitimate provider the oral era therefore raises the premium attaching to two gates. Supply integrity rises in importance because counterfeit pressure flows toward whatever is most readily faked, with the result that the provenance of stock becomes a patient safety fact which patients will increasingly enquire about. And the patient-source conversation rises in importance because an applicant commencing with a service may be switching from a product of unknown origin, which materially alters the clinical picture. A service which asks, without judgement, what a person has already been taking and where it originated is performing harm reduction which the black market cannot.

What does declining well involve?

A verification framework carries meaning only insofar as it produces refusals, and refusals constitute clinical work rather than lost revenue. Decline with a reason the patient can understand. Record the decision with the care applied to a supply, covering what was checked, what failed or flagged, and what was advised. Redirect to the GP or an appropriate service in preference to leaving the applicant to approach the next provider with weaker checks.

Circumvention attempts warrant treatment as information rather than merely as obstruction. Implausible figures, resubmissions under variant details and pressure to omit steps indicate fraud in certain cases, desperation in others, and occasionally an eating disorder presenting as determination. In each case the record should hold the observation and the superintendent's governance should see it in aggregate. The providers whom regulators cited for prescribing targets had optimised for approval, and a defensible service is one whose refusals are documented, humane and sufficiently frequent to be credible.

What evidence pack does scrutiny request?

The following functions as a self-audit, in the spirit of our inspection guide, since these are the artefacts which an inspector, or a coroner, would request from a weight-loss service.

The service specification and standard operating procedures, current and specific to weight-loss supply rather than adapted boilerplate. The verification method statement, establishing how height and weight are independently determined, with sampled records demonstrating that it occurs. The prescriber governance file, identifying who prescribes, their independence from commercial outcomes, and how refusals are reviewed.

A run of patient journeys end to end, from application to review, including at least one refusal and one stopped treatment, since a service with no examples of either is exhibiting a symptom. The duplication and multi-provider check design. Procurement records tracing stock to licensed wholesalers. The counselling content covering the contraception and pancreatitis warnings, with evidence of delivery rather than of linking. The recall log demonstrating that missed reviews were pursued. And the aggregate governance pack, comprising refusal rates, flag themes and incident learning, evidencing that someone senior examines the whole.

A provider able to produce that pack within an afternoon is not merely compliant. Such a provider also holds the strongest marketing claim available within this category, which is demonstrable dissimilarity from the market the surveys describe.

Key takeaways

FAQs